Octreotide in the treatment of inoperable hepatocellular carcinoma

This item is provided by the institution :

Repository :
Annals of Gastroenterology
see the original item page
in the repository's web site and access all digital files if the item*

2007 (EN)
Octreotide in the treatment of inoperable hepatocellular carcinoma (EN)

A. Ilias, Ch. Gessiou, V. Tzarou, G. Kokozidis, G. Kitis, T. Patsanas, D. Kapetanos,

SUMMARY Background & Aims: The progression and therapy of hepatocellular carcinoma (HCC) may be influenced by somatostatin-receptors in HCC cells. This has offered the rationale for evaluating the therapeutic usefulness of octreotide in patients with HCC. The aim of this study was to assess the clinical and biochemical impact of octreotide administration in patients with HCC. Method: Thirty patients with HCC, who were unsuitable for surgery, ethanol injection or transarterial embolization were divided into two groups (A and B) according to the presence or not of cirrhosis. All patients received 500ìg octreotide subcutaneously twice daily indefinitely. Results: Mean survival time was 5+1.3 months in group A and 8.3+0.96 months in group B, with significant differences between the two groups (log rank test, p=0.03). Cirrhotic patients with Okuda I+II stage had a longer survival time in comparison to patients with Okuda III stage (log rank test, p=0.04). Moreover, octreotide administration stopped gradual elevation of a-fetoprotein (AFP) levels. Conclusions: Octreotide seems to improve the survival time in non-cirrhotic patients with HCC and especially in patients with Okuda II stage with no elevation of AFP, offering acceptable quality of life, safety and tolerance. (EN)




Hellenic Society of Gastroenterology (EN)

Annals of Gastroenterology; Volume 17, No 1 (2004) (EN)

*Institutions are responsible for keeping their URLs functional (digital file, item page in repository site)